News IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Delayed Nasdaq Stockholm Other stock markets 06:59:54 2024-04-30 am EDT			5-day change	1st Jan Change
11.4 ^SEK	+1.33%		-0.87%	+52.00%

Mar. 22	IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam	CI
Mar. 19	IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IRLAB publishes Annual Report for 2023	Apr. 29	AQ
IRLAB to present at Redeye Investor Forum	Apr. 16	AQ
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam	Mar. 25	AQ
IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam	Mar. 22	CI
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam	Mar. 22	AQ
IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis	Mar. 19	CI
IRLAB Therapeutics : mesdopetam displays antipsychotic properties in an advanced model of Parkinson's disease psychosis	Mar. 19	PU
IRLAB’s mesdopetam displays antipsychotic properties in an advanced model of Parkinson’s disease psychosis	Mar. 19	AQ
IRLAB to present at Life Science-dagen in Gothenburg and have a fireside chat with ABG	Feb. 29	AQ
IRLAB to present at the Bayes@Lund 2024 Conference in Lund, Sweden on March 7	Feb. 28	AQ
IRLAB to present clinical and preclinical data at the AD/PD™ 2024: 18th International Conference on Alzheimer’s & Parkinson’s Diseases	Feb. 27	AQ
IRLAB has completed a successful End-of-Phase 2 meeting with the FDA on the design of the Phase III program for mesdopetam	Feb. 22	AQ
IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam	Feb. 22	CI
IRLAB's pioneering Phase IIb study with pirepemat, React-PD, provides new insights in specific Parkinson's patient population and enables a data driven prediction of study timelines	Feb. 07	AQ
Transcript : IRLAB Therapeutics AB, 2023 Earnings Call, Feb 07, 2024	Feb. 07
IRLAB publishes year-end report for the period January-December 2023	Feb. 07	AQ
IRLAB Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 07	CI
IRLAB’s pioneering Phase IIb study with pirepemat – React-PD – provides new insights in specific Parkinson’s patient population and enables a data driven prediction of study timelines	Feb. 06	AQ
IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines	Feb. 06	CI
IRLAB, Invitation to the Year-end Report 2023 presentation and webcast	Feb. 01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Summary

Filters